Commodore Capital LP 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Commodore Capital LP disclosed 31 US equity positions worth $1.4bn in its Q1 2025 13F filing. The largest position was MERUS N V at 13.9% of the reported book, followed by NUVALENT INC and ELVN. Against the Q4 2024 filing, it opened 4 new positions, added to 13 and reduced 4 among the top 31 holdings.
What did Commodore Capital LP own in Q1 2025? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 13.9% | $188.3m | 4,472,840 | 15% | added | |
| 2 | NUVALENT INC | 9.7% | $131.6m | 1,855,000 | 14% | added | |
| 3 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.8% | $92.0m | 4,675,000 | 11% | added |
| 4 | SLNOEUR SOLENO THERAPEUTICS INC | 6.1% | $82.2m | 1,150,000 | -25% | reduced | |
| 5 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.7% | $78.0m | 2,325,000 | -15% | reduced |
| 6 | ALKS ALKERMES PLC | Healthcare | 4.7% | $64.4m | 1,950,000 | -15% | reduced |
| 7 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.7% | $64.0m | 2,185,000 | – | new |
| 8 | PCVX VAXCYTE INC | Healthcare | 4.6% | $62.3m | 1,650,000 | 2% | added |
| 9 | VERA VERA THERAPEUTICS INC | Healthcare | 4.5% | $61.5m | 2,561,782 | 31% | added |
| 10 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 4.3% | $58.1m | 3,200,000 | – | new |
| 11 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 4.1% | $56.1m | 1,745,000 | 84% | added |
| 12 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.9% | $53.3m | 8,892,816 | 29% | added |
| 13 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 3.6% | $48.5m | 3,600,000 | 50% | added |
| 14 | NRIX NURIX THERAPEUTICS INC | Healthcare | 3.5% | $47.3m | 3,978,907 | 33% | added |
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.5% | $34.0m | 2,367,578 | 7% | added | |
| 16 | SYRE SPYRE THERAPEUTICS INC | 2.4% | $32.1m | 1,988,084 | 0% | held | |
| 17 | PHVS PHARVARIS N V | 2.2% | $30.0m | 1,911,433 | 0% | held | |
| 18 | BRD1EUR MIND MEDICINE MINDMED INC | 2.0% | $26.5m | 4,525,000 | 5% | added | |
| 19 | SLDB SOLID BIOSCIENCES INC | Healthcare | 1.6% | $21.6m | 5,825,000 | – | new |
| 20 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.3% | $18.0m | 500,000 | 0% | held |
| 21 | CRDF CARDIFF ONCOLOGY INC | 1.2% | $16.9m | 5,384,616 | 0% | held | |
| 22 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.1% | $14.6m | 1,419,714 | 0% | held |
| 23 | IKT INHIBIKASE THERAPEUTICS INC | 0.9% | $11.7m | 5,344,432 | -10% | reduced | |
| 24 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.8% | $11.2m | 2,000,000 | 0% | held |
| 25 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.8% | $10.8m | 290,000 | 0% | held |
| 26 | NGNE NEUROGENE INC | 0.8% | $10.8m | 925,000 | 16% | added | |
| 27 | TYRA TYRA BIOSCIENCES INC | Healthcare | 0.7% | $8.8m | 950,000 | – | new |
| 28 | PERCEPTIVE CAP SOLUTIONS COR | 0.6% | $7.7m | 750,000 | 0% | held | |
| 29 | CELC CELCUITY INC | Healthcare | 0.5% | $7.0m | 695,650 | 74% | added |
| 30 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $3.9m | 1,575,000 | 0% | held | |
| 31 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.3% | $3.9m | 483,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.